| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and cash equivalents | $10.5M+1117.3% | $862K-95.9% | $21.3M-48.2% | $41.0M |
| Short-term investments | $7.4M | — | — | — |
| Amounts receivable and prepaid expenses | $2.1M-26.2% | $2.8M-51.0% | $5.7M | — |
| Total current assets | $19.9M+445.4% | $3.7M-86.4% | $26.9M-36.4% | $42.3M |
| Equity investment in BC Therapeutics | $524K+25.3% | $418K | — | — |
| Intangible assets, net | $185K-7.6% | $200K-7.1% | $215K-6.6% | $230K |
| Property and equipment, net | $297K-23.5% | $388K | — | — |
| Long term prepaid expenses | $718K-40.8% | $1.2M | — | — |
| Total non-current assets | $1.7M-22.3% | $2.2M+931.5% | $215K-6.6% | $230K |
| Total assets | $21.6M+268.7% | $5.9M-78.4% | $27.2M-36.2% | $42.6M |
| Trade payables | $3.3M-54.2% | $7.2M+538.1% | $1.1M+142.6% | $463K |
| Accrued expenses and other payables | $694K+139.1% | $290K-57.2% | $678K+41.8% | $478K |
| Total current liabilities | $4.0M-46.7% | $7.5M+314.2% | $1.8M+91.4% | $941K |
| Warrant liability | $338K-69.2% | $1.1M-96.2% | $29.1M-6.9% | $31.3M |
| Total non-current liabilities | $338K-69.2% | $1.1M-96.2% | $29.1M-6.9% | $31.3M |
| Share Capital of no par value – Authorized: unlimited at July 31, 2025 and 2024; Issued and outstanding: 1,883,906 and 121,907 shares at July 31, 2025 and 2024, respectively | $101.7M+41.0% | $72.2M+3.7% | $69.6M+6.1% | $65.6M |
| Share-based payment reserved | $10.3M+12.3% | $9.2M+23.8% | $7.4M+42.0% | $5.2M |
| Warrant reserve | $17.7M+860.7% | $1.8M | — | — |
| Accumulated other comprehensive loss | -$139K+0.0% | -$139K+0.0% | -$139K+0.0% | -$139K |
| Non-controlling interest | -$547K-80.7% | -$303K | — | — |
| Accumulated deficit | -$111.8M-30.8% | -$85.4M-5.9% | -$80.7M-33.6% | -$60.3M |
| Total shareholders’ equity (deficit) | $17.3M+745.6% | -$2.7M+28.9% | -$3.8M-136.6% | $10.3M |
| Total liabilities and shareholders’ equity (deficit) | $21.6M+268.7% | $5.9M-78.4% | $27.2M-36.2% | $42.6M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.